Trial reportBlood2026
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.
Trial report in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04245839 (A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractIn the TRANSCEND FL primary analysis, lisocabtagene maraleucel (liso-cel) showed high response rates and favorable safety in patients with relapsed/refractory (R/R) follicular lymphoma (FL). Longer follow-up is needed to assess remission durability and long-term or late-onset toxicities. Here, we report 3-year follow-up results (median on-study follow-up, 41.5 months [range, 0.3-54.0]) in patients with third-line or later (3L+) FL. Patients had R/R FL after ≥2 previous lines of combination systemic therapy, including an anti-CD20 antibody and an alkylator. A total of 107 patients received liso-cel and 103 were efficacy evaluable, with overall and complete response rates per independent review committee of 97% (95% confidence interval [CI], 92-99) and 94% (95% CI, 88-98), respectively. Medians were not reached for all time-to-event outcomes; estimated 36-month rates for duration of response, progression-free survival, time free from next treatment, and overall survival were 70% (95% CI, 60-78), 68% (95% CI, 58-76), 75% (95% CI, 70-80), and 86% (95% CI, 78-92), respectively. Response rates and 36-month time-to-event rates were consistent in high-risk subgroups, including patients with disease progression within 24 months of starting first-line immunochemotherapy, bulky disease, or double-refractory status. Longitudinal safety analyses showed decreasing grade ≥3 cytopenias and hypogammaglobulinemia (immunoglobulin G <500 mg/dL), with use of supportive care (transfusions, growth factors, IV immunoglobulin) mostly limited to the 3 months after infusion, and consistently low incidences of grade ≥3 infections in short- and long-term periods. At 3-year follow-up, a single liso-cel infusion delivered durable efficacy and high survival, including in high-risk subgroups, alongside a favorable long-term safety profile in patients with 3L+ FL. This trial was registered at www.clinicaltrials.gov as NCT04245839.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.